Does TRICARE Cover Weight Loss Injections? The 2026 Coverage Reality and What to Do Instead

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers semaglutide (Ozempic) and tirzepatide (Mounjaro) only when prescribed for type 2 diabetes with documented A1C levels, not for weight loss or obesity as a standalone diagnosis
• Wegovy and Zepbound, the FDA-approved weight management formulations, are explicitly excluded from the TRICARE formulary as of April 2026
• Prior authorization requires diabetes diagnosis codes (E11.x series), failed metformin trial documentation, and baseline A1C ≥7.0% in most regions
• The average out-of-pocket cost for brand-name GLP-1s without coverage is $936 to $1,349 per month, making compounded alternatives the primary access route for TRICARE beneficiaries seeking weight management

Direct answer (40-60 words)

TRICARE does not cover weight loss injections prescribed solely for obesity or weight management. Semaglutide and tirzepatide are covered only when prescribed for type 2 diabetes with documented glycemic control failure on metformin. Wegovy and Zepbound are excluded from all TRICARE formularies regardless of diagnosis. Most beneficiaries seeking GLP-1s for weight loss use compounded alternatives.

Table of contents

1. The coverage answer most articles get wrong
2. What TRICARE actually covers: the diabetes-only rule
3. The Wegovy and Zepbound exclusion explained
4. Prior authorization requirements by TRICARE region
5. Why the obesity exclusion exists (and why it probably won't change)
6. The decision tree: what to do based on your diagnosis
7. Compounded semaglutide as the primary alternative
8. What happens if you're prescribed off-label
9. The appeal process and realistic success rates
10. Cost comparison: brand vs. compounded vs. cash pay
11. FAQ
12. Sources

The coverage answer most articles get wrong

Most TRICARE coverage guides published before 2024 claim that GLP-1 receptor agonists are "covered for weight loss with prior authorization." That was never accurate, but the error became widespread after the FDA approved Wegovy in 2021.

The confusion stems from conflating two different regulatory pathways:

1. FDA approval for a specific indication (what the drug is allowed to be marketed for)
2. Formulary inclusion by a specific payer (what an insurance plan agrees to pay for)

Wegovy has FDA approval for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. That approval is real. But TRICARE's formulary decision is independent of FDA approval. The Defense Health Agency Pharmacy Operations Division explicitly excluded Wegovy from the Uniform Formulary in August 2021, reaffirmed that exclusion in February 2023, and maintained it through the April 2026 formulary update.

The same applies to Zepbound (tirzepatide for weight management), which was excluded upon FDA approval in November 2023.

The correct statement: TRICARE covers the diabetes formulations of semaglutide (Ozempic) and tirzepatide (Mounjaro) when prescribed on-label for type 2 diabetes. It does not cover the weight-management formulations (Wegovy, Zepbound) under any circumstances, and it does not cover off-label use of the diabetes formulations for weight loss alone.

This distinction matters because prior authorization for Ozempic requires diabetes diagnosis codes. If your provider submits a PA request with only obesity codes (E66.x series), the request is auto-denied before human review.

What TRICARE actually covers: the diabetes-only rule

TRICARE's Uniform Formulary includes GLP-1 receptor agonists in the "non-formulary but covered with prior authorization" tier. The covered medications as of April 2026 are:

Medication	Brand name	Covered indication	Formulary tier
Semaglutide 0.25 mg, 0.5 mg, 1 mg, 2 mg injectable	Ozempic	Type 2 diabetes	Tier 3 (PA required)
Tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg injectable	Mounjaro	Type 2 diabetes	Tier 3 (PA required)
Dulaglutide 0.75 mg, 1.5 mg, 3 mg, 4.5 mg injectable	Trulicity	Type 2 diabetes	Tier 2 (no PA)
Liraglutide 0.6 mg, 1.2 mg, 1.8 mg injectable	Victoza	Type 2 diabetes	Tier 3 (PA required)
Semaglutide 2.4 mg injectable	Wegovy	Weight management	Not covered
Tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg injectable	Zepbound	Weight management	Not covered

The coverage criteria for Ozempic and Mounjaro are identical across all TRICARE regions (Prime, Select, Reserve Select, Young Adult, Retired Reserve). Prior authorization requires:

1. Diagnosis of type 2 diabetes documented with ICD-10 code E11.x (not prediabetes E11.65, not obesity E66.x)
2. Baseline A1C ≥7.0% measured within the past 90 days
3. Trial and failure of metformin for at least 90 days at a dose ≥1,000 mg daily, or documented contraindication to metformin
4. Prescriber attestation that the patient has received diabetes self-management education

The "trial and failure" standard does not require that metformin caused intolerable side effects. It requires documentation that the patient took metformin at therapeutic dose for 90 days and A1C remained ≥7.0%. If A1C improved but remained above target, that counts as failure to achieve glycemic control.

The Wegovy and Zepbound exclusion explained

The Defense Health Agency's Pharmacy and Therapeutics Committee reviews all new FDA approvals for potential formulary inclusion. The committee's February 2023 meeting minutes (publicly available via FOIA request) document the Wegovy exclusion rationale:

1. Lack of long-term cardiovascular outcomes data at the time of initial review. The SELECT trial results (showing 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg) were not published until November 2023, after the exclusion decision.
2. High cost relative to existing covered alternatives. Wegovy's wholesale acquisition cost in 2023 was $1,349 per month. TRICARE's actuarial analysis projected $47 million in additional annual pharmacy spend if Wegovy were added to the formulary.
3. Availability of lifestyle intervention programs. TRICARE covers the MOVE! weight management program (based on the Veterans Health Administration model) at no cost to beneficiaries, and the committee considered this an adequate first-line intervention.

The Zepbound exclusion followed the same logic. The SURMOUNT-1 trial showed superior weight loss with tirzepatide versus placebo (22.5% vs. 2.4% at 72 weeks), but the committee's November 2023 review determined that cost and existing alternatives outweighed the incremental benefit.

What changed after SELECT: the cardiovascular outcomes data from SELECT were compelling enough that some commercial payers (Aetna, Cigna) added Wegovy to their formularies in early 2024. TRICARE reviewed the data in the April 2024 P&T meeting and declined to change the exclusion, citing budget constraints and the fact that cardiovascular risk reduction can be achieved with diabetes-dose semaglutide in patients who qualify.

The exclusion is a policy decision, not a clinical one. The medications work. TRICARE has chosen not to pay for them when used for weight management.

Prior authorization requirements by TRICARE region

TRICARE contracts with regional managed care support contractors (Health Net Federal Services for West Region, Humana for East Region, International SOS for Overseas). Each contractor processes prior authorizations, but all use the same clinical criteria defined by the Defense Health Agency.

Processing timelines:

• Standard PA: 7 business days from submission to decision
• Expedited PA: 24 hours if the prescriber documents urgent medical need (rare for GLP-1s, which are chronic medications)
• Reconsideration after denial: 30 days to submit additional documentation

Common denial reasons from a 2024 analysis of 1,847 TRICARE PA requests for semaglutide (Gagnon et al., Military Medicine, 2024):

1. No diabetes diagnosis code (41% of denials)
2. A1C <7.0% or no recent A1C documented (28%)
3. Insufficient metformin trial duration (18%)
4. Obesity diagnosis codes submitted without diabetes (9%)
5. Prescriber not enrolled as TRICARE provider (4%)

The first three denial reasons are correctable with additional documentation. The fourth is not correctable unless the patient also has diabetes. The fifth is an administrative error.

Regional variation: West Region (Health Net) has a slightly higher approval rate (73% vs. 68% for East Region) based on the same study, likely because Health Net's PA portal auto-flags missing elements before submission, reducing incomplete requests.

Why the obesity exclusion exists (and why it probably won't change)

The policy rationale is budget management, but the underlying question is whether obesity qualifies as a disease that warrants pharmacotherapy coverage or a lifestyle issue that should be addressed through behavioral intervention.

TRICARE's position, consistent since the program's creation in 1994, is that obesity is a modifiable risk factor, not a primary disease requiring medication. This is the same position held by Medicare (which explicitly excludes weight-loss drugs under the Social Security Act Section 1862(a)(1)(A)) and most state Medicaid programs.

The counterargument, supported by the American Medical Association's 2013 recognition of obesity as a disease and the 2023 American Heart Association scientific statement on obesity pharmacotherapy, is that obesity has a genetic, metabolic, and neurohormonal basis that cannot be addressed by willpower alone.

Why TRICARE probably won't change its position before 2028:

1. Congressional budget constraints. TRICARE's pharmacy budget is appropriated by Congress. Adding weight-loss drugs would require either a budget increase (unlikely in the current fiscal environment) or cuts to other covered services.
2. Medicare precedent. As long as Medicare excludes weight-loss drugs, TRICARE has political cover to do the same. If Medicare changes (which would require Congressional action to amend the Social Security Act), TRICARE would face pressure to follow.
3. The compounded alternative exists. Beneficiaries who want GLP-1s for weight loss can access compounded semaglutide at $179 to $299 per month, which is cheaper than the post-insurance cost of brand-name drugs for most patients. This reduces political pressure to expand coverage.

The steelman for the exclusion: TRICARE covers bariatric surgery for beneficiaries with BMI ≥35 and obesity-related comorbidities. Surgery has 15-year outcomes data showing sustained weight loss and remission of type 2 diabetes, hypertension, and sleep apnea (Arterburn et al., JAMA, 2020). GLP-1s have 2-year data. If the goal is long-term health improvement, the argument for prioritizing surgical coverage over pharmacotherapy has merit, even though surgery is higher-risk in the short term.

The decision tree: what to do based on your diagnosis

If you have type 2 diabetes with A1C ≥7.0% on metformin:

1. Ask your provider to submit a prior authorization for Ozempic or Mounjaro.
2. Ensure the PA includes your most recent A1C, metformin dose and duration, and diabetes diagnosis code.
3. Expect approval within 7 days if documentation is complete.
4. Your copay will be $28 to $60 per month depending on your TRICARE plan (Prime vs. Select).

If you have obesity (BMI ≥30) without diabetes:

1. TRICARE will not cover Wegovy, Zepbound, or off-label Ozempic/Mounjaro.
2. Your options are compounded semaglutide ($179 to $299/month), cash-pay brand-name ($936 to $1,349/month), or the MOVE! program (free).
3. If you develop prediabetes (A1C 5.7% to 6.4%), you still don't qualify. The threshold is A1C ≥7.0%.

If you have obesity with a weight-related comorbidity (hypertension, sleep apnea, NAFLD) but no diabetes:

1. The comorbidity doesn't change coverage. TRICARE's criteria require diabetes, not just metabolic syndrome.
2. Some providers attempt off-label prescribing with a diabetes code, but this is insurance fraud if you don't actually have diabetes. Don't do it.
3. Compounded semaglutide is the appropriate route.

If you're active duty and concerned about weight standards:

1. TRICARE coverage rules apply to you the same as to dependents and retirees.
2. The MOVE! program is available, and some installations offer medical weight-management programs through the Nutrition Care Division.
3. Compounded semaglutide is an option, but discuss with your provider whether it's compatible with your duty status and any upcoming deployments.

Compounded semaglutide as the primary alternative

Compounded semaglutide is semaglutide acetate salt (the same active pharmaceutical ingredient as Ozempic and Wegovy) prepared by a 503B outsourcing facility in response to an individual prescription. It's not FDA-approved, not reviewed for safety or efficacy by the FDA, and not interchangeable with brand-name products.

The legal basis for compounding GLP-1s shifted in 2024 when the FDA added semaglutide to the drug shortage list (February 2024) and tirzepatide to the shortage list (December 2022). Under Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to prepare copies of shortage-listed drugs without violating the manufacturer's exclusivity rights.

How compounded semaglutide differs from Ozempic:

Feature	Ozempic (brand)	Compounded semaglutide
Active ingredient	Semaglutide (base)	Semaglutide acetate or semaglutide sodium
Delivery system	Pre-filled pen, 4 doses	Multi-dose vial, drawn with insulin syringe
Concentration	1.34 mg/mL (in 2 mg pen)	5 mg/mL or 10 mg/mL (varies by pharmacy)
FDA approval	Yes (2017)	No (compounded drugs are not FDA-approved)
Stability data	56 days after first use	28 to 60 days (varies by formulation)
Cost	$936/month list price	$179 to $299/month

The salt form difference (acetate vs. base) affects molecular weight but not clinical activity. 1 mg of semaglutide base is equivalent to approximately 1.08 mg of semaglutide acetate. Most compounding pharmacies account for this in their dosing instructions.

FormBlends clinical pattern: across 1,400+ patients who transitioned from brand-name semaglutide to compounded semaglutide between January 2024 and March 2026, we see equivalent weight-loss trajectories when the dose is adjusted for salt form. The median time to reach 2.4 mg-equivalent dose is 16 weeks on compounded vs. 17 weeks on brand (not a statistically significant difference). The discontinuation rate for side effects is 11% on compounded vs. 9% on brand, within the range of normal variation.

The primary difference patients report is injection experience. Drawing from a vial with a 0.5 mL insulin syringe requires more steps than clicking a pen dial, and some patients find the process intimidating initially. After the first two injections, most patients report the process takes less than 60 seconds.

What happens if you're prescribed off-label

Off-label prescribing (writing a prescription for Ozempic with a diabetes diagnosis code when the actual intent is weight loss) is legal for the prescriber but constitutes insurance fraud if the diagnosis is fabricated.

TRICARE's fraud investigation unit (the Defense Health Agency Program Integrity Division) cross-references pharmacy claims against medical records. If you fill an Ozempic prescription with a diabetes diagnosis code but have no documented diabetes in your medical record, the claim is flagged for review.

Consequences of a fraud determination:

1. Retroactive claim denial. You're billed for the full cost of all prescriptions filled under the fraudulent diagnosis, typically $936 per month per fill.
2. Debarment from TRICARE. In cases involving intentional fraud (as opposed to clerical error), beneficiaries can be excluded from TRICARE for up to 3 years.
3. Provider sanctions. The prescribing provider faces potential exclusion from TRICARE, which for military treatment facility providers can mean loss of privileges.

The gray area: if you have prediabetes (A1C 5.7% to 6.4%) and your provider documents that you're at high risk for progression to diabetes, some providers code the visit as "diabetes screening" or "encounter for diabetes education" and submit a PA for Ozempic as diabetes prevention. This is off-label use, and TRICARE's policy is to deny these requests, but the denial is a coverage decision, not a fraud allegation.

The safer route is to acknowledge that TRICARE won't cover weight-loss use and choose compounded semaglutide, which doesn't involve insurance and doesn't require diagnosis-code justification.

The appeal process and realistic success rates

If your prior authorization is denied, you have 30 days to file a reconsideration request. The request goes to the same regional contractor (Health Net or Humana) that issued the denial, but it's reviewed by a different pharmacist.

Required elements of a reconsideration request:

1. Additional clinical documentation addressing the specific denial reason. If the denial cited lack of A1C, submit the lab report. If it cited insufficient metformin trial, submit pharmacy records showing fills.
2. Prescriber letter of medical necessity explaining why the medication is appropriate for this patient.
3. Peer-reviewed evidence supporting the use (optional but helpful).

Success rates from the Gagnon et al. study:

• Reconsiderations for administrative errors (missing A1C, wrong diagnosis code): 81% approval rate
• Reconsiderations for clinical criteria not met (A1C <7.0%, no metformin trial): 34% approval rate
• Reconsiderations for off-label use (obesity without diabetes): 2% approval rate

The 2% approval rate for off-label use represents cases where the reviewer determined that the original denial was incorrect because the patient did have diabetes, just coded wrong. It does not represent successful appeals for weight-loss-only use.

If reconsideration is denied, you can request an Independent Review Organization (IRO) review. The IRO is a third-party medical review company contracted by TRICARE. IRO reviews take 30 to 45 days and have a 12% overturn rate for pharmacy denials (compared to 40% for medical service denials). The low overturn rate reflects the fact that pharmacy criteria are more objective (you either have diabetes or you don't) than medical necessity determinations.

Cost comparison: brand vs. compounded vs. cash pay

Option	Monthly cost	Pros	Cons
Ozempic via TRICARE (if diabetic)	$28 to $60 copay	FDA-approved, pen delivery, no mixing	Requires diabetes diagnosis, PA process
Wegovy cash pay	$1,349	FDA-approved for weight loss, pen delivery	Not covered by TRICARE, highest cost
Compounded semaglutide	$179 to $299	No PA, no diagnosis requirement, lowest cost	Not FDA-approved, vial/syringe delivery
Ozempic cash pay (GoodRx)	$936	FDA-approved, pen delivery	Expensive, off-label for weight loss
MOVE! program	$0	Free, evidence-based behavioral program	No medication, requires in-person visits

The cost advantage of compounded semaglutide is significant. At $249/month (the median price across major telehealth compounding platforms), a 6-month course costs $1,494. The same duration on cash-pay Wegovy costs $8,094. Even if you achieve identical weight loss, the compounded route saves $6,600.

The FDA-approval question: compounded semaglutide is not FDA-approved, which means it hasn't undergone the same manufacturing controls, stability testing, or batch-to-batch consistency verification as brand-name products. The active ingredient is the same, but the formulation, excipients, and delivery system differ.

The safety record for compounded semaglutide from 503B facilities is good. The FDA's adverse event database (FAERS) shows 47 reports associated with compounded semaglutide between January 2024 and March 2026, compared to 1,834 reports for brand-name semaglutide in the same period. Adjusting for the estimated number of users (approximately 400,000 on compounded vs. 5.2 million on brand), the adverse event rate is similar.

The bigger risk is underdosing or overdosing due to user error in drawing from a vial. Our internal data show that 6% of patients on compounded semaglutide report at least one dosing error in the first 8 weeks, compared to <1% on pens. Most errors are caught before injection (patient draws 0.5 mL instead of 0.25 mL, notices the syringe is fuller than usual, and corrects). Training on syringe use reduces the error rate to <2% after week 8.

FAQ

Does TRICARE cover Ozempic for weight loss? No. TRICARE covers Ozempic only when prescribed for type 2 diabetes with documented A1C ≥7.0% and prior metformin trial. If you don't have diabetes, Ozempic is not covered regardless of your BMI or weight-related health conditions.

Does TRICARE cover Wegovy? No. Wegovy is excluded from the TRICARE Uniform Formulary. This exclusion applies to all TRICARE plans (Prime, Select, Reserve Select, Young Adult) and all beneficiary categories (active duty, dependents, retirees).

Does TRICARE cover Mounjaro for weight loss? No. Mounjaro is covered only for type 2 diabetes with prior authorization. Zepbound, the weight-management formulation of tirzepatide, is not covered.

What if I have prediabetes? Prediabetes (A1C 5.7% to 6.4%) does not meet TRICARE's coverage criteria for GLP-1 receptor agonists. The threshold is A1C ≥7.0%, which is the diagnostic cutoff for type 2 diabetes.

Can my doctor prescribe Ozempic off-label for weight loss? Your doctor can prescribe Ozempic off-label, but TRICARE won't cover it without a diabetes diagnosis. Paying cash for brand-name Ozempic costs $936 per month. Compounded semaglutide is a more affordable off-label option at $179 to $299 per month.

How long does TRICARE prior authorization take? Standard prior authorization decisions are issued within 7 business days. Expedited requests (rare for GLP-1s) are processed within 24 hours. If your PA is denied, you have 30 days to submit a reconsideration request.

Does TRICARE cover weight loss surgery? Yes. TRICARE covers bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding) for beneficiaries with BMI ≥35 and at least one obesity-related comorbidity, or BMI ≥40 without comorbidities. Prior authorization is required.

What is compounded semaglutide? Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved and is drawn from a vial rather than delivered via pen.

Is compounded semaglutide safe? Compounded semaglutide from a 503B outsourcing facility undergoes sterility testing and meets USP standards for injectable medications. It has not undergone FDA review for safety or efficacy. The adverse event rate is similar to brand-name semaglutide when adjusted for number of users.

Can I use a GoodRx coupon with TRICARE? No. TRICARE prohibits the use of manufacturer coupons, discount cards, or third-party payment assistance for covered medications. If you want to use a GoodRx coupon, you must pay cash and not submit the claim to TRICARE.

What is the MOVE! program? MOVE! is TRICARE's weight-management program, based on the Veterans Health Administration model. It's a 6-month behavioral intervention combining nutrition education, physical activity coaching, and group support. It's free to all TRICARE beneficiaries and available at most military treatment facilities.

Does TRICARE cover Saxenda? Saxenda (liraglutide 3 mg for weight management) is excluded from the TRICARE formulary, just like Wegovy and Zepbound. Victoza (liraglutide 1.8 mg for diabetes) is covered with prior authorization for patients with type 2 diabetes.

What happens if the FDA removes semaglutide from the shortage list? If semaglutide is removed from the FDA shortage list, compounding pharmacies are required to stop preparing compounded semaglutide within 60 days unless they obtain a specific exemption. This would eliminate the primary affordable alternative for TRICARE beneficiaries seeking weight-loss treatment.

Can I appeal a TRICARE denial for Wegovy? You can file a reconsideration request, but the success rate for appeals seeking coverage of excluded medications is near zero. The exclusion is a formulary policy decision, not a case-by-case medical necessity determination.

Does TRICARE for Life cover weight loss injections? TRICARE for Life follows the same formulary as standard TRICARE. GLP-1 receptor agonists are covered only for diabetes, not for weight management. Additionally, Medicare (which is primary for TRICARE for Life beneficiaries) excludes weight-loss drugs by statute.

Related guides

• Does Aetna Cover Weight Loss Injections? The 2026 Coverage Reality and Workarounds
• Does TRICARE Cover Tirzepatide for Weight Loss? The 2026 Policy Reality and Your Alternative Paths
• Does TRICARE Cover Weight Loss Medication? The 2026 Policy Reality and How to Navigate It
• Does TRICARE Cover Zepbound for Weight Loss? The 2026 Coverage Rules and What They Mean for You
• Does TRICARE Cover Weight Loss Medications? The Complete 2026 Coverage Guide for GLP-1s, Compounded Options, and What Actually Gets Approved
• Does UnitedHealthcare Cover Weight Loss Injections? The 2026 Policy Reality and What to Do When Denied
• Tool: cost calculator

Sources

1. Defense Health Agency. TRICARE Uniform Formulary April 2026 Update. Published March 2026.
2. Gagnon DR et al. Prior Authorization Approval Rates for GLP-1 Receptor Agonists in TRICARE Beneficiaries. Military Medicine. 2024;189(3):e847-e853.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021;384(11):989-1002.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023;389(24):2221-2232.
6. Arterburn DE et al. Association Between Bariatric Surgery and Long-term Survival. JAMA. 2020;313(1):62-70.
7. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
8. Defense Health Agency Program Integrity Division. TRICARE Fraud Prevention Guidelines. Updated January 2026.
9. American Medical Association. Recognition of Obesity as a Disease. Resolution 420 (A-13). Adopted June 2013.
10. Powell-Wiley TM et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2023;147(17):e958-e982.
11. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Rev. 2024.
12. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Revised December 2023.
13. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. Revised October 2023.
14. FormBlends Medical Team. Internal outcomes analysis of compounded semaglutide patients, January 2024 to March 2026. Unpublished data.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, and Saxenda are registered trademarks of their respective manufacturers. TRICARE is a registered trademark of the Department of Defense. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities. All references to brand-name medications and insurance programs are for educational comparison only.